LIFECORE BIOMEDICAL, INC. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock
LIFECORE BIOMEDICAL, INC. (LFCR) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock of 0 shares for the 12-month period ending 2025-05-25, per its 10-K filed 2025-08-07.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock · last filed 2026-03-16
- LIFECORE BIOMEDICAL, INC. incremental common shares attributable to dilutive effect of conversion of preferred stock for the quarter ending 2025-02-23 was 0.00 shares, a 100.00% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. incremental common shares attributable to dilutive effect of conversion of preferred stock for the quarter ending 2024-11-24 was 0.00 shares, a 100.00% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. incremental common shares attributable to dilutive effect of conversion of preferred stock for the quarter ending 2024-02-25 was 5.90M shares.
- LIFECORE BIOMEDICAL, INC. incremental common shares attributable to dilutive effect of conversion of preferred stock for the quarter ending 2023-11-26 was 5.79M shares.
- LIFECORE BIOMEDICAL, INC. incremental common shares attributable to dilutive effect of conversion of preferred stock for fiscal 2025 was 0.00 shares, a 100.00% decline from fiscal 2024.
- LIFECORE BIOMEDICAL, INC. incremental common shares attributable to dilutive effect of conversion of preferred stock for fiscal 2024 was 5.85M shares.
- LIFECORE BIOMEDICAL, INC. incremental common shares attributable to dilutive effect of conversion of preferred stock for fiscal 2023 was 0.00 shares.
- LIFECORE BIOMEDICAL, INC. incremental common shares attributable to dilutive effect of conversion of preferred stock for fiscal 2022 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 3 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 6 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 9 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 12 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-05-25 | 0.00 shares 10-K · filed 2025-08-07 | |||||||
| 2025-02-23 | 0.00 shares 10-Q · filed 2025-04-03 | 0.00 shares 10-Q · filed 2025-04-03 | ||||||
| 2024-11-24 | 0.00 shares 10-Q · filed 2025-01-02 | 0.00 shares 10-Q · filed 2025-01-02 | ||||||
| 2024-05-26 | 5.85M shares 10-KT · filed 2026-03-16 | 5.85M shares 10-K · filed 2024-08-26 | ||||||
| 2024-02-25 | 5.90M shares 10-Q · filed 2025-04-03 | 5.90M shares 10-Q · filed 2024-08-09 | 5.79M shares 10-Q · filed 2025-04-03 | 5.79M shares 10-Q · filed 2024-08-09 | ||||
| 2023-11-26 | 5.79M shares 10-Q · filed 2025-01-02 | 5.79M shares 10-Q · filed 2024-08-09 | 5.74M shares 10-Q · filed 2025-01-02 | 5.74M shares 10-Q · filed 2024-08-09 | ||||
| 2023-05-28 | 0.00 shares 10-K · filed 2024-08-26 | |||||||
| 2023-02-26 | 0.00 shares 10-Q · filed 2024-08-09 | 0.00 shares 10-Q · filed 2024-08-09 | ||||||
| 2022-11-27 | 0.00 shares 10-Q · filed 2024-08-09 | 0.00 shares 10-Q · filed 2024-08-09 | ||||||
| 2022-05-29 | 0.00 shares 10-K · filed 2024-08-26 | |||||||
| 2022-02-27 | 0.00 shares 10-Q · filed 2023-06-02 | 0.00 shares 10-Q · filed 2023-06-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |